Study of ADCT-301 in Patients With Selected Advanced Solid Tumors

Stopped Cami in combination with pembrolizumab in solid tumors showed signals of immunomodulatory activity. However, the signals were insufficiently compelling at the tested dose/schedule to justify continuation of the study.

Conditions

• Head and Neck Cancer Squamous Cell Carcinoma
• Non-small Cell Lung Cancer
• Gastric Cancer
• Esophageal Cancer
• Pancreas Cancer
• Bladder Cancer
• Renal Cell Carcinoma
• Melanoma
• Triple-negative Breast Cancer
• Ovarian Cancer
• Colo-rectal Cancer
• Fallopian Tube Cancer

Interventions

• DRUG: ADCT-301
• BIOLOGICAL: Pembrolizumab

Sponsor

ADC Therapeutics S.A.